Navigation Links
Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:2/10/2011

SAN DIEGO, Feb. 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Optimer. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Jefferies & Company, Inc. is acting as the sole book-running manager for the proposed offering and Baird, Canaccord Genuity Inc., JMP Securities, Needham & Company, LLC, and ThinkEquity LLC are acting as co-managers for the proposed offering.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340 and at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Optimer Pharmaceuticals, Inc.Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the proposed public offering of securities by Optimer. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to market conditions and the satisfaction of customary closing conditions, and other risks detailed in Optimer's filings with the SEC.  All forward-looking statements are qualified in their entirety by this cautionary statement, and Optimer undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
2. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
3. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
4. Optimer Pharmaceuticals Announces Key Additions to Management Team
5. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
6. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
7. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
8. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
9. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
10. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
11. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... the world , s first dual therapy ... intervention   OrbusNeich, a global company specializing ... its portfolio to include products to treat peripheral artery ... company,s first entry devices for lower limb and arteriovenous ...
(Date:5/24/2016)... -- Open Access Journal Focusing on ... Elsevier , a world-leading provider of scientific, technical ... launch of Clinical Neurophysiology Practice ... clinical practice issues in clinical neurophysiology. The journal will ... and didactic reviews. It is an official journal of ...
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
Breaking Medicine Technology:
(Date:5/26/2016)... San Diego, CA (PRWEB) , ... May 26, 2016 , ... ... operation with him running plumbing calls throughout the beach community. His vision to grow ... at affordable rates and ensuring they maintain the highest level of training and customer ...
(Date:5/26/2016)... ... May 26, 2016 , ... According to the Webster’s dictionary, a ... with chemical-laden beauty products, one company is going against the norm with a line ... The rising star in the green space is proud to announce its latest retail ...
(Date:5/26/2016)... ... May 26, 2016 , ... HealthPostures, ergonomics designer and ... , furniture that may support women during pregnancy. Potential benefits of using the Stance ... rest and comfort and healthier levels of sitting and standing. , Need for the ...
(Date:5/25/2016)... Miami, Florida (PRWEB) , ... May 26, 2016 , ... ... for the treatment of androgenetic alopecia in both men and women. To date, the ... laser caps with FDA clearance for any adult who suffers with androgenetic alopecia. ...
(Date:5/25/2016)... Chicago, IL (PRWEB) , ... May 25, 2016 ... ... HealthScape Advisors,” said Steven Young, a Managing Partner at HealthScape Advisors. “Brad brings ... value-based care within the healthcare delivery system accelerates with the implementation of MACRA, ...
Breaking Medicine News(10 mins):